Polfa Sa Tarchomin
TZF Polfa is a Polish pharmaceutical manufacturer and contract manufacturer (CMO/CDMO) founded in 1823, producing 50+ prescription and OTC products, APIs, and sterile injectable drugs for hospitals, pharmacies, and pharmaceutical companies worldwide.
- Company typePrivate
- Founded1823
- HeadquartersWarszawa, Poland
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Polfa Sa Tarchomin does
TZF Polfa is a Polish pharmaceutical manufacturer headquartered in Warsaw and the oldest pharmaceutical company in Poland, founded in 1823. It operates as an S.A. (Spółka Akcyjna) with registered capital of PLN 184,913,610 and an employee base of 5,001–10,000. The company produces over 50 products in 130 forms and doses spanning prescription drugs (Rx) — including antibiotics, human insulins, dermatological, and CNS medications — alongside over-the-counter (OTC) products, dietary supplements, dermocosmetics, and the PolhuminPen insulin injector. It also manufactures active pharmaceutical ingredients (APIs).
The company's core technology platform centers on a modern OEB 5 high-potency drug production line — one of the most advanced in Central-Eastern Europe — coupled with 12,000+ m² of production space including 3,000 m² of cleanrooms class C and higher. In October 2025, TZF Polfa unveiled a new High-Potency Drug Development and Production Center for injectable products, and in 2025 launched a dedicated OEB 5 parenteral laboratory conducting over 4,000 tests annually. Operations comply with cGMP standards for EU, FDA, and EAEU markets, and the company is responsible for producing 10% of the EU critical medicines list.
TZF Polfa monetizes through three revenue streams: contract manufacturing (CMO/CDMO) of APIs and finished dosage forms for pharmaceutical clients, direct B2B sales of proprietary and manufactured products to hospitals, pharmacies, and medical facilities (delivering 25 million packages annually worldwide), and laboratory services covering preformulation and analytical testing. Go-to-market is enterprise-direct via hospital procurement systems and pharmaceutical distribution networks, with quote-based pricing. The customer base spans public and private hospitals, retail and hospital pharmacies, and pharmaceutical companies seeking CMO/CDMO capacity, particularly for high-potency injectable and sterile parenteral products.
Polfa Sa Tarchomin firmographics
Firmographics- Name
- Polfa Sa Tarchomin
- Legal name
- Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
- Website
- https://polfa-tarchomin.com.pl
- Company type
- Private
- Founded year
- 1823
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- TZF Polfa is a Polish pharmaceutical manufacturer and contract manufacturer (CMO/CDMO) founded in 1823, producing 50+ prescription and OTC products, APIs, and sterile injectable drugs for hospitals, pharmacies, and pharmaceutical companies worldwide.
- Ownership category
- akta.pro rank
Polfa Sa Tarchomin industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Polfa Sa Tarchomin is headquartered
LocationHeadquarters
- HQ city
- Warszawa
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Polfa Sa Tarchomin business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Infrastructure, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Contract Manufacturing (CMO/CDMO): Revenue from contract manufacturing of active pharmaceutical ingredients (API) and finished dosage forms (FDF) for pharmaceutical companies. Services include preformulation, analytical support, and production of high-potency drugs and parenteral products.
- Pharmaceutical Product Sales: Revenue from sale of proprietary and manufactured pharmaceutical products including prescription drugs (Rx), over-the-counter (OTC) products, dietary supplements, and dermocosmetics. Distribution to hospitals, pharmacies, and medical facilities.
- Laboratory Services: Revenue from laboratory services including preformulation studies, analytical testing (over 4,000 tests annually), and quality control for pharmaceutical products.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Polfa Sa Tarchomin product offering
Product offeringCore offering
TZF Polfa manufactures and supplies a portfolio of over 50 pharmaceutical products in 130 forms and dosages, including prescription drugs (antibiotics, human insulins, dermatological and CNS drugs), OTC products, dietary supplements, dermocosmetics, and active pharmaceutical ingredients (APIs). The company also provides contract manufacturing (CMO/CDMO) services for API and finished dosage forms with one of Central-Eastern Europe's most modern OEB 5 high-potency drug production lines, along with preformulation and analytical laboratory services.
Product overview
TZF Polfa is a pharmaceutical company offering a portfolio of over 50 products in 130 forms and doses. The core offerings include prescription medications (Rx) such as antibiotics, human insulins, dermatological drugs, and CNS medications; over-the-counter products (OTC); dietary supplements; and dermocosmetics. The company also manufactures active pharmaceutical ingredients (APIs) and PolhuminPen injectors. Supporting the product portfolio are contract manufacturing services (CMO/CDMO) with one of the most modern high-potency drug (OEB 5) production lines in Central-Eastern Europe, and laboratory services including preformulation and analytical support with over 4000 annual tests. The company delivers 25 million packages annually to hospitals, pharmacies, and medical facilities, and is responsible for 10% of the EU critical medicines list production.
Differentiator
Problem solved
Functional benefit
Products and services
- Prescription Medications (Rx)
Quantifiable outcome
- Production of 10% of EU critical medicines list
- +3 more outcomes
Companies that use Polfa Sa Tarchomin
Customer profileSegments3 records
Ideal customer profiles3 records
Polfa Sa Tarchomin technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Polfa Sa Tarchomin partnerships and signals
Strategic signalScale indicators7 records
Recent moves5 records
Expansion highlights4 records
Polfa Sa Tarchomin competitors and assessment
Company assessmentDirect peers
- KRKA: Slovenian-led generic pharmaceutical manufacturer with a strong CEE, Central Asian, and Eastern European footprint. Closely comparable in scale, finished-dose generics focus, and multi-region manufacturing footprint.
- Polpharma: Poland's largest pharmaceutical manufacturer and TZF Polfa's most direct domestic competitor. Operates a comparable generic Rx portfolio, FDF manufacturing, and contract services across CEE, with similar hospital and pharmacy distribution channels.
- Hikma Pharmaceuticals: UK-listed generic and specialty pharmaceutical company with a leading injectables franchise. Directly comparable to TZF Polfa's sterile parenteral and high-potency injectable manufacturing focus, including CMO/CDMO relationships with hospital customers.
- Recipharm: European CDMO providing contract development and manufacturing services for APIs and finished dosage forms. Directly comparable to TZF Polfa's CMO/CDMO service line, including high-potency and sterile fill-finish capabilities for pharma clients.
- Gedeon Richter: Hungarian pharmaceutical group combining branded originator and generic drug manufacturing with significant European and CIS-market reach. Overlaps with TZF Polfa in generics, women's health, and CEE/CIS distribution channels.
- Zentiva: One of Europe's largest generic pharmaceutical manufacturers, headquartered in the Czech Republic with deep CEE roots. Targets the same hospital, pharmacy, and tender procurement channels as TZF Polfa with overlapping therapeutic-area coverage in generics.
Emerging players
- Alvotech: Icelandic biosimilars developer and manufacturer focused on sterile injectable biologics. Partial overlap with TZF Polfa's parenteral and high-potency manufacturing, but specialised in biosimilars rather than small-molecule generics.
Broad incumbents
- Sandoz: Recently spun off from Novartis as the world's largest standalone generics and biosimilars company. Competes with TZF Polfa in generic Rx and biosimilars-adjacent injectables, but from a much larger platform with global commercial reach.
- Stada Arzneimittel: German-headquartered European generic and specialty pharmaceutical company with strong retail-pharmacy and CEE distribution. Comparable in generic FDF product breadth and European CDMO positioning to TZF Polfa.
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with global API and FDF operations. A broader incumbent player in the same product categories as TZF Polfa, but at vastly greater scale and with much broader therapeutic and geographic reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Polfa Sa Tarchomin social profiles
Digital presencePolfa Sa Tarchomin compliance and trust
Trust signalCompliance3 records
Polfa Sa Tarchomin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Polfa Sa Tarchomin leadership team
Management profileNumber of profiles
Profiles3 records
Polfa Sa Tarchomin funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Polfa Sa Tarchomin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Polfa Sa Tarchomin
What does Polfa Sa Tarchomin do?
TZF Polfa manufactures and supplies a portfolio of over 50 pharmaceutical products in 130 forms and dosages, including prescription drugs (antibiotics, human insulins, dermatological and CNS drugs), OTC products, dietary supplements, dermocosmetics, and active pharmaceutical ingredients (APIs). The company also provides contract manufacturing (CMO/CDMO) services for API and finished dosage forms with one of Central-Eastern Europe's most modern OEB 5 high-potency drug production lines, along with preformulation and analytical laboratory services.
Is Polfa Sa Tarchomin a public or private company?
Polfa Sa Tarchomin is a private company. It is classified as unknown and is currently operating.
When was Polfa Sa Tarchomin founded?
Polfa Sa Tarchomin was founded in 1823. It employs 5,001 to 10,000 people.
Where is Polfa Sa Tarchomin based?
Polfa Sa Tarchomin is headquartered in Warszawa, Poland, in the Europe region.
How does Polfa Sa Tarchomin make money?
Three revenue lines are on record. Contract Manufacturing (CMO/CDMO) is the primary driver. The others are pharmaceutical Product Sales and laboratory Services.
Who are Polfa Sa Tarchomin's main competitors?
Direct peers on record are KRKA, Polpharma, Hikma Pharmaceuticals, Recipharm, Gedeon Richter and Zentiva. Alvotech is listed as an emerging player. Broad incumbents are Sandoz, Stada Arzneimittel and Teva Pharmaceutical Industries.
Does Polfa Sa Tarchomin have an API?
No public API is recorded for Polfa Sa Tarchomin.
What industry is Polfa Sa Tarchomin in?
Polfa Sa Tarchomin's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.